Mitochondrial myopathies caused by prolonged use of telbivudine

http://www.e-acn.org pISSN 2508-691X eISSN 2508-6960 Copyright © 2017 The Korean Society of Clinical Neurophysiology This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http:// creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Mitochondrial myopathies caused by prolonged use of telbivudine

[1]  K. Wong,et al.  Clinicopathological Features of Telbivudine-Associated Myopathy , 2016, PloS one.

[2]  R. Thimme,et al.  Natural history of chronic hepatitis B virus infection , 2015, Medical Microbiology and Immunology.

[3]  Huiqiong Zhou,et al.  Entecavir‐associated myopathy: A case report and literature review , 2014, Muscle & nerve.

[4]  Eun Hye Kim,et al.  Two cases of telbivudine-induced myopathy in siblings with chronic hepatitis B , 2013, Clinical and molecular hepatology.

[5]  J. Jia,et al.  Telbivudine myopathy in a patient with chronic hepatitis B , 2012, International Journal of Clinical Pharmacy.

[6]  X. Zou,et al.  Clinical features and risk factors of creatine kinase elevations and myopathy associated with telbivudine , 2011, Journal of viral hepatitis.

[7]  Dong Kuck Lee,et al.  Long‐term therapy with clevudine for chronic hepatitis B can be associated with myopathy characterized by depletion of mitochondrial DNA , 2009, Hepatology.

[8]  M. Manns,et al.  Trial Results : Telbivudine Is Superior to Lamivudine in atients With Chronic Hepatitis B UN – , 2022 .

[9]  Y. Lo,et al.  Continuous single motor unit electromyographic activity in adefovir associated myopathy , 2008, Journal of Clinical Neuroscience.

[10]  G. Fattovich,et al.  Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. , 2008, Journal of hepatology.

[11]  R. Hamatake,et al.  Entecavir for Treatment of Hepatitis B Virus Displays No In Vitro Mitochondrial Toxicity or DNA Polymerase Gamma Inhibition , 2007, Antimicrobial Agents and Chemotherapy.

[12]  Ò. Miró,et al.  Clinical, histological and molecular reversibility of zidovudine myopathy , 1998, Journal of the Neurological Sciences.

[13]  H. Reichmann,et al.  Mitochondrial myopathy caused by long-term zidovudine therapy. , 1990, The New England journal of medicine.